Childhood Cancer

You are here

Pre-clinical Evaluation of LSD1 Inhibitors for the Treatment of Pediatric Ewing sarcoma: Defining the Biomarkers of Sensitivity and Mechanisms of Resistance

Institution: 
Research Institute at Nationwide Children's Hospital
Researcher(s): 
Kathleen Pishas, PhD
Grant Type: 
Young Investigator Grants
Year Awarded: 
2016
Type of Childhood Cancer: 
Ewing Sarcoma
Project Description: 

Background

The development of drug resistance to both traditional chemotherapeutic and new targeted agents remains a major impediment and primary challenge in the quest to treat Ewing sarcoma, a highly aggressive pediatric solid bone malignancy. Despite significant advances in our understanding of the drivers of Ewing sarcoma oncogenesis, treatment strategies remain restricted to non-specific multi-modal regiments encompassing chemotherapy, radiotherapy and surgery. Five year overall survival rates for patients with metastatic disease remain at 10-20%. In addition, current chemotherapeutic treatment regimens are associated with significant cumulative and late toxicities. Given the modest efficacy of current sarcoma therapeutic modalities, there is a major unmet clinical need for the translation of novel agents to tackle the global burden of pediatric sarcoma. 

Several studies have documented lysine specific demethylase 1 (LSD1) overexpression in highly malignant tumors including Ewing sarcoma. Our laboratory has recently shown that treatment of Ewing sarcoma cell lines with the novel LSD1 inhibitor HCI-2509 induces potent cell death and disrupts the global transcriptional function of EWS-FLI, the defining translocation associated with Ewing sarcoma. 

Project Goal

As HCI-2509 will enter Phase I clinical testing in 2016, the primary objective of this study is to elucidate the biomarkers of response and mechanism(s) of resistance to LSD1 inhibitors prior to clinical trial evaluation. Our findings will provide a clear strategy for the incorporation of LSD1 targeted therapies into the treatment armamentarium for Ewing sarcoma and how we can circumvent drug resistance to achieve maximal therapeutic effect.

"As an early career researcher, funding from Alex's Lemonade Stand Foundation will allow me to undertake pioneering research in collaboration with leading experts to decipher the mechanisms by which Ewing sarcoma cells develop drug resistance to inhibitors of LSD1, a promising therapeutic target for the treatment of pediatric cancers." - Kathleen Pishas, PhD

Co-funded by: 
Flashes of Hope